Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807323 | 0.93 | NPC1 (0.49) | NPC1RAB9AKMT2APTGESALOX5 | |
| SCHEMBL2157707 | 0.91 | PTGES (0.45) | NPC1RAB9AKMT2APTGESALOX5 | |
| SCHEMBL2158675 | 0.86 | CRHBP (0.47) | NPC1RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL3809793 | 0.86 | NPC1 (0.41) | STAT3NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL2158296 | 0.86 | P2RY14 (0.37) | PTGESALOX5 | |
| SCHEMBL2456970 | 0.85 | MAPT (0.42) | ALDH1A1POLB | |
| SCHEMBL2158096 | 0.84 | PTGES (0.61) | NPC1RAB9APTGESALOX5 | |
| SCHEMBL2878956 | 0.84 | ALDH1A1 (0.43) | NPC1RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL2157942 | 0.83 | — | — | |
| SCHEMBL2158010 | 0.83 | PTGES (0.45) | NPC1RAB9AKMT2APTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | claimed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | claimed |
| EP-1401825-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | VIROCHEM PHARMA INC (CA) | 2009-08-05 | — | — | EP | claimed |
| CN-100509797-C | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2009-07-08 | — | — | CN | claimed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | claimed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | claimed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| EP-2363396-A1 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2011-09-07 | — | — | EP | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| CN-101624391-A | Thiophene derivatives as antiviral agents for flavivirus infection | VIROCHEM PHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| EP-1401825-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | VIROCHEM PHARMA INC (CA) | 2009-08-05 | — | — | EP | disclosed |
| CN-100509797-C | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2009-07-08 | — | — | CN | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | STAT3 3068/4885NPC1 30/4885RAB9A 1333/4885 |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | STAT3 3068/4885NPC1 30/4885RAB9A 1333/4885 |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | STAT3 3068/4885NPC1 30/4885RAB9A 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.